toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author (up) Magrath, J.W.; Kim, Y. url  doi
  Title Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review) Type Journal Article
  Year 2017 Publication International Journal of Oncology Abbreviated Journal Int J Oncol  
  Volume 51 Issue 3 Pages 753-759  
  Abstract Glioblastoma multiforme (GBM) is the most common and deadliest form of primary brain tumor. Despite treatment with surgery, radiotherapy, and chemotherapy with the drug temozolomide, the expected survival after diagnosis remains low. The median survival is only 14.6 months and the two-year survival is a mere 30%. One reason for this is the heterogeneity of GBM including the presence of glioblastoma cancer stem cells (GSCs). GSCs are a subset of cells with the unique ability to proliferate, differentiate, and create tumors. GSCs are resistant to chemotherapy and radiation and thought to play an important role in recurrence. In order to effectively treat GBM, a drug must be identified that can kill GSCs. The ionophore salinomycin has been shown to kill cancer stem cells and is therefore a promising future treatment for GBM. This study focuses on salinomycin's potential to treat GBM including its ability to reduce the CSC population, its toxicity to normal brain cells, its mechanism of action, and its potential for combination treatment.  
  Address Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487-0203, USA  
  Corporate Author Thesis  
  Publisher Place of Publication Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Edition  
  ISSN 1019-6439 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:28766685 Approved no  
  Call Number ref @ user @ Serial 96573  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: